Lithium and Nephrogenic diabetes insipidus: is the FAERS signal real?
Lithium ↔ Nephrogenic diabetes insipidus
Long-term lithium, the cornerstone mood stabiliser in bipolar disorder, commonly causes a concentrating defect in the kidney — nephrogenic diabetes insipidus — in which the tubules stop responding to antidiuretic hormone, leading to excessive urination and thirst. It usually develops after months to years of treatment and may be partly reversible if the drug is stopped early. The very high PRR (301.3) reflects that this is a characteristic, almost signature lithium toxicity rather than an idiosyncratic event, and it is why kidney function and fluid balance are monitored during lithium therapy.
Regulatory basis: lithium prescribing information (nephrogenic diabetes insipidus and renal monitoring). Established lithium-nephrotoxicity literature.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | met | Polyuria and polydipsia develop after months–years of lithium and may improve on withdrawal |
| Strength | met | Very high PRR, characteristic of the drug |
| Consistency | met | Reproduced across decades of lithium-nephrotoxicity studies |
| Specificity | met | A signature lithium effect, unlike most drugs |
| Biological gradient | met | Related to cumulative exposure and duration |
| Plausibility | met | Tubular resistance to antidiuretic hormone is the defined mechanism |
| Coherence | met | Coheres with the labelled renal monitoring during lithium therapy |
| Experiment | partial | Dechallenge (withdrawal) may partially reverse it; no randomized trial |
| Analogy | met | Analogous to other drug-induced nephrogenic diabetes insipidus (e.g. demeclocycline) |
This page's own qualitative read, not an automated/citation-gated assessment.